EDITORIAL DESK / CORRESPONDENCE
Contact Boston Peptide
Notes about source accuracy, regulatory context, and careful corrections are welcome.
Editorial correspondence
Boston Peptide welcomes messages about the record: a citation that no longer resolves, wording that extends beyond its source, a relevant peer-reviewed paper, or a regulatory status that needs review. The most useful note identifies the page, quotes the passage, and supplies the supporting source. That structure allows the desk to check the complete context rather than revise from a headline alone.
Editorial mailbox: editors@bostonpeptide.com
The mailbox is intended for research and editorial correspondence. It is not monitored as a clinical service, and replies may not be immediate. Published corrections are made when the underlying record supports them. Commercial placement, product review, supplier listing, and affiliate requests fall outside the scope of this independent digest.
What the desk can address
Suitable topics include citation accuracy, study design, evidence classification, plain-language clarity, compound identity, and Massachusetts-US regulatory framing. Notes about GHK-Cu, semaglutide, tesamorelin, or BPC-157 are reviewed against the same rule used throughout the site: the confidence of the sentence must match the quality and scope of the source.
The desk cannot assess symptoms, recommend treatment, evaluate a personal regimen, interpret laboratory results for an individual, or direct anyone to a compound source. Requests involving urgent health concerns belong with qualified local care. Questions about an approved prescription product belong in a licensed clinician-patient or pharmacist-patient setting. Competitive-sport questions require the current rules from the relevant governing body.
This separation protects the purpose of the project. Boston Peptide is built to improve reading of the research record, document corrections, and keep unresolved questions visible.